Data from a phase III trial demonstrate that zinc-α 2-glycoprotein (AZGP1) status at radical prostatectomy is predictive of outcomes of patients with prostate cancer, after a median follow-up duration of 15.8 years. Biopsy samples from a total of 347 patients undergoing radical prostatectomy were analysed using immunohistochemistry. Low or absent AZGP1 expression was found to be an independent predictor of a short biochemical-relapse-free survival duration, relative to mean levels of AZGP1 and also improved the discriminatory value of existing prognostic risk models. These findings indicate the clinical merit of AZGP1 expression as a prognostic biomarker in men with prostate cancer.
References
Zhang, A. Y. et al. A prospective multi-centre phase III validation study of AZGP1 as a biomarker in localised prostate cancer. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdx247 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. AZGP1 expression predicts favourable outcomes. Nat Rev Urol 14, 391 (2017). https://doi.org/10.1038/nrurol.2017.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.83